专利号:US-2008287407-A1 优先权日:2003-12-10 标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use 发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI 权利人:NITROMED INC 摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.
专利号:US-5043448-A 优先权日:1989-07-27 标 题:Asymmetric synthesis of furo(3,4-c) pyridine derivatives 发明人:ECK CHARLES 权利人:SCRAS 摘要:The invention relates to a method for the preparation of a non-racemic furo [3,4-c] pyridine derivatives of the formula I ##STR1## wherein R 1 , R 2 and R 3 stand for various substitutents, comprising adding a concentrated strong acid to a solution of a non-racemic compound of the formula II ##STR2## in an amount sufficient to catalyze a deprotection/cyclodehydration. These compounds are known antihypertensives.
专利号:AT-399151-B 优先权日:1989-07-27 标题:ASYMMETRICAL SYNTHESIS OF FURO (3,4-C) PYRIDINE DERIVATIVES
专利号:CN-101678118-A 优先权日:2006-10-05 标 题:Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
专利号:NL-9001612-A 优先权日:1989-07-27 标 题:ASYMMETRICAL SYNTHESIS OF FURO3,4-C PYRIDINE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THE NON-RACEMIC, PHARMACEUTICALLY ACTIVE DERIVATIVES.
专利号:SE-509680-C2 优先权日:1989-07-27 标 题:Asymmetric synthesis of furo (3,4-c) pyridine derivatives
1: Choi EY, Ro Y, Choi JW, Kang CM, Kim GH. Cicletanine-induced hyponatremia and hypokalemia in kidney transplant patients. Kidney Res Clin Pract. 2016 Sep;35(3):142-6. doi: 10.1016/j.krcp.2016.05.004. Epub 2016 May 25. 2: Kalinowski L, Szczepańska-Konkel M, Jankowski M, Angielski S. Cicletanine: new insights into its pharmacological actions. Gen Pharmacol. 1999 Jul;33(1):7-16. doi: 10.1016/s0306-3623(98)00257-2. 19(2):181-9. doi: 10.1097/00005344-199202000-00005. 13(5):571-6. doi: 10.1111/j.1472-8206.1999.tb00363.x. 26(3):236-41. doi: 10.1046/j.1440-1681.1999.03021.x. 43(25):2103-15. doi: 10.1016/0024-3205(88)90360-8. 305(2):G163-71. doi: 10.1152/ajpgi.00003.2013. Epub 2013 May 2. 8: Wagner F, Malice MP, Wiegert E, McGrath HE, Gildea J, Mitta S, Van Dyck K, De Lepeleire I, Johnson-Levonas AO, Sisk CM, Fernandez R, Greenwalt DM, Beals C, Carey RM, Nunes I. A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans. J Hypertens. 2012 Apr;30(4):819-27. doi: 10.1097/HJH.0b013e32835022a8. 21 Suppl
合成参考文献
参考文献:10.2165/00003495-199300462-00013 摘要:Safar ME, Lévy BI. Mechanical function and histological structure of the arterial wall. The response to antihypertensive treatment. Drugs. 1993;46 Suppl 2():68–74. doi: 10.2165/00003495-199300462-00013. 参考文献:10.1023/a:1007835821228 摘要:Reyes AJ, Taylor SH. Diuretics in cardiovascular therapy: the new clinicopharmacological bases that matter. Cardiovasc Drugs Ther. 1999 Sep;13(5):371–98. doi: 10.1023/a:1007835821228.